ScoreWhy is Pyxis Oncology, Inc. ?
1
Flat results in Sep 25
- NET SALES(9M) At USD 2.82 MM has Grown at -82.53%
- ROCE(HY) Lowest at -87.28%
- PRE-TAX PROFIT(Q) Lowest at USD -22 MM
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 13.33%, its profits have fallen by -32.7%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Pyxis Oncology, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Pyxis Oncology, Inc.
19.17%
-0.57
115.12%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
30.74%
EBIT Growth (5y)
-342.70%
EBIT to Interest (avg)
-65.66
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.02
Sales to Capital Employed (avg)
0.08
Tax Ratio
2.22%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
67.57%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.51
EV to EBIT
-0.33
EV to EBITDA
-0.34
EV to Capital Employed
-3.81
EV to Sales
9.89
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-110.68%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
NET PROFIT(HY)
Higher at USD -40.36 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at -85.28 %
-12What is not working for the Company
NET SALES(9M)
At USD 2.82 MM has Grown at -82.53%
ROCE(HY)
Lowest at -87.28%
PRE-TAX PROFIT(Q)
Lowest at USD -22 MM
NET PROFIT(Q)
Lowest at USD -22 MM
Here's what is working for Pyxis Oncology, Inc.
Debt-Equity Ratio
Lowest at -85.28 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Pyxis Oncology, Inc.
Net Sales
At USD 2.82 MM has Grown at -82.53%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
Lowest at USD -22 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -22 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
